Literature DB >> 31071352

Kinase inhibitors tyrphostin 9 and rottlerin block early steps of rabies virus cycle.

Zoé Lama1, Yves Gaudin1, Danielle Blondel1, Cécile Lagaudrière-Gesbert2.   

Abstract

Rabies virus (RABV) is a neurotropic virus that causes fatal encephalitis in humans and animals and still kills up to 59,000 people worldwide every year. To date, only preventive or post-exposure vaccination protects against the disease but therapeutics are missing. After screening a library of 80 kinases inhibitors, we identified two compounds as potent inhibitors of RABV infection: tyrphostin 9 and rottlerin. Mechanism of action studies show that both inhibitors interfere with an early step of viral cycle and can prevent viral replication. In presence of tyrphostin 9, the viral entry through endocytosis is disturbed leading to improper delivery of viral particles in cytoplasm, whereas rottlerin is inhibiting the transcription, most likely by decreasing intracellular ATP concentration, and therefore the replication of the viral genome.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Entry inhibitor; Rabies virus (RABV); Rottlerin; Transcription inhibitor; Tyrphostin 9

Mesh:

Substances:

Year:  2019        PMID: 31071352     DOI: 10.1016/j.antiviral.2019.04.014

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  4 in total

1.  Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor.

Authors:  Venice Du Pont; Christoph Wirblich; Jeong-Joong Yoon; Robert M Cox; Matthias J Schnell; Richard K Plemper
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

2.  Rottlerin plays an antiviral role at early and late steps of Zika virus infection.

Authors:  Shili Zhou; Quanshi Lin; Changbai Huang; Xiaotong Luo; Xu Tian; Chao Liu; Ping Zhang
Journal:  Virol Sin       Date:  2022-08-05       Impact factor: 6.947

3.  Optimization of Inhibitory Peptides Targeting Phosphoprotein of Rabies Virus.

Authors:  Yongzhong Lu; Linyue Cheng; Jie Liu
Journal:  Int J Pept Res Ther       Date:  2019-08-13       Impact factor: 1.931

4.  A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection.

Authors:  Fangyuan Chen; Qingya Shi; Fen Pei; Andreas Vogt; Rebecca A Porritt; Gustavo Garcia; Angela C Gomez; Mary Hongying Cheng; Mark E Schurdak; Bing Liu; Stephen Y Chan; Vaithilingaraja Arumugaswami; Andrew M Stern; D Lansing Taylor; Moshe Arditi; Ivet Bahar
Journal:  Mol Syst Biol       Date:  2021-08       Impact factor: 11.429

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.